792 related articles for article (PubMed ID: 23877261)
1. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
[TBL] [Abstract][Full Text] [Related]
3. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
4. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner.
Karsy M; Albert L; Tobias ME; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2010 Dec; 30(12):4915-20. PubMed ID: 21187470
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
7. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
9. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
[TBL] [Abstract][Full Text] [Related]
10. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
11. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
12. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.
Jhanwar-Uniyal M; Albert L; McKenna E; Karsy M; Rajdev P; Braun A; Murali R
Adv Enzyme Regul; 2011; 51(1):164-70. PubMed ID: 21035497
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Jones NM; Rowe MR; Shepherd PR; McConnell MJ
Int J Oncol; 2016 Jul; 49(1):207-16. PubMed ID: 27176780
[TBL] [Abstract][Full Text] [Related]
16. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways.
Aeder SE; Martin PM; Soh JW; Hussaini IM
Oncogene; 2004 Dec; 23(56):9062-9. PubMed ID: 15489897
[TBL] [Abstract][Full Text] [Related]
17. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
18. The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Tumour Biol; 2014 May; 35(5):4567-80. PubMed ID: 24399651
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.
Albert L; Karsy M; Murali R; Jhanwar-Uniyal M
Cancer Genomics Proteomics; 2009; 6(5):255-61. PubMed ID: 19996130
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
